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ABSTRACT 
 
Baclofen is a highly used centrally acting GABA agonist that continues to be an effective therapy for symptomatic 
relief of skeletal muscle spasm and spasticity in traumatic spinal cord lesions, multiple sclerosis, cerebral palsy, 
stroke and chronic hiccups and has recently become popular as recreational drug. The renally dependent excretion 
determines the circulating concentrations and guides effective dosing to decrease adverse reactions. Caution should 
be considered in administering baclofen to patients with decreased renal function. We present a patient with end 
stage renal disease on hemodialysis with recent baclofen ingestion who presented with toxic encephalopathy that 
was resolved with additional dialysis sessions. 
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Introduction 
Baclofen (parachlorophenyl gamma-aminobutyric acid) 
is an agonist of the neurotransmitter gamma-
aminobutyric acid (GABA) [1] with centrally 
functioning mechanism of action has been used to treat 
spasticity and more recently chronic hiccups [2, 3]. 
Baclofen is well absorbed in the gastrointestinal tract 
producing the determined therapeutic levels of 80–
400 ng/mL [4]. The primary excretion is through the 
kidney (70–80%) with the remainder metabolized in 
the liver or processed through the gastrointestinal tract 
[4]. Only a small portion is able to cross the blood 
brain barrier, creating the desired effects. The half-life 
is approximately 6.8 hours [3]. Patients with decreased 
renal function have an extended half-life with more 
crossing of the blood brain barrier. The generalized 
central nervous system (CNS) depression effects are 
then further pronounced producing fatigue, syncope, 
hypotension, ataxia, psychological disturbances, and 
cardiovascular and respiratory depression [2, 4].In 
patients with limited renal function, there have been 
reports of toxic side effects with the initial dosing of 
5 mg three times a day within only a few days [5] and 
baclofen effects can be prolonged in these patients. 
Baclofen toxicity has been shown to resolve with 
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hemodialysis resembling excretion rates similar to 
normal renal function [6]. Here we report a case of 
baclofen-induced encephalopathy in a dialysis patient 
with recovery following hemodialysis sessions. 
 
Case presentation 
Our patient is a 73-year-old female with a past medical 
history of end stage renal disease on hemodialysis, 
diabetes mellitus type 2, hypertension, coronary artery 
disease status post coronary artery bypass graft, 
hyperlipidemia and peripheral vascular disease status 
post angioplasty who presented for altered mental 
status. The patient had a recent primary care physician 
visit with concern for low back pain due to muscle 
spasm and was started on baclofen 10 mg twice a day. 
On the day of admission, the patient was found to be 
speaking incoherently, repeatedly mumbling words like 
“okay” and “hold on”, confused and unable to 
concentrate. The vital signs were the following: 
temperature 99 °F, respiratory rate 18 breaths/minute, 
pulse 81 beats/minute, blood pressure 142/88 mmHg 
and pulse oxygenation 99% on room air. On initial 
presentation, the patient was lethargic but arousable 
and unable to answer questions. She was not alert or 
oriented to herself or her surroundings. She did not 
have fever, headache, neck stiffness, nausea, vomiting, 
seizures or head injury. She had not traveled recently 
or had any sick contacts. Laboratory tests showed the 
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following: sodium 138 mEq/L, potassium 4.3 mEq/L, 
chloride 97 mEq/L, bicarbonate 29 mEq/L, blood urea 
nitrogen 42 mg/dL, creatinine 4.9 mg/dL. The white 
blood cell count was 8.5 mg/dL, hemoglobin 
11.1 mg/dL, and platelet count 237/mm3. Hepatic 
function panel had a total bilirubin of 0.7 mg/dL, AST 
29 u/L, ALT 39 u/L, alkaline phosphatase 120 u/L, 
creatine kinase 350 u/L, thyroid stimulating hormone 
1.4 and ammonia 23 u/L. Her arterial blood gas was 
normal and toxicology screen was negative. A head 
computed tomography and MRI was performed with 
no acute intracranial abnormalities and chest x ray was 
normal as well. Compliance with her last hemodialysis 
session was confirmed. With high suspicion for 
baclofen-induced encephalopathy, the patient was 
admitted for emergent dialysis. She received 
hemodialysis for two sessions with significant 
improvement in mental status without any residual 
symptoms. Upon discharge, the patient had baclofen 
discontinued 
Discussion 
Baclofen was originally found to be effective in 
treatment of spasticity concerning spinal cord lesions in 
the 1960s [7]. The mechanism of action is a centrally 
acting presynaptic agonist of GABA to enhance tone 
reduction and reduce spasticity [1]. In recent studies, it 
has been shown effective in treating persistent hiccups 
[3]. Baclofen is efficiently absorbed in the 
gastrointestinal tract and with variations of the half-life 
dependent largely on renal function being the primary 
mechanism of excretion [4]. A high correlation 
between renal clearance and creatinine clearance was 
shown to exist in a excretion kinetic study [8].Baclofen 
is a moderately lipophilic molecule and with increased 
circulating concentration crossing the blood brain 
barrier has a correlating amplified centrally acting 
response [9]. These adverse reactions include 
hypotension, bradycardia, respiratory depression, and 
toxic encephalopathy [5, 9]. There have been previous 
cases with chronic renal failure and symptoms of 
neurotoxicity. Serum concentrations of baclofen were 
measured to have progressively decreased during the 
sessions of hemodialysis with resolution of the 
neurologic sequel [5]. The effectiveness of 
hemodialysis was additionally seen in another case of 
baclofen overdose with normal renal function. In this 
case, a patient consumed 200 mg of extended release 
baclofen with subsequent ventilator dependent 
respiratory failure. Two sessions resolved the side 
effects with successful extubation and resolution of 
additional symptoms [9].In a study of the efficiency in 
using hemodialysis, the filtration rate for baclofen was 
as effective as normal kidneys [6]. This high efficiency 
of filtration is because only 30% of the circulating 
concentration is bound to protein [6]. In case reports, 
there is a several-hour delay prior to improvement in 
symptoms with the theorized necessity of redistribution 
from the CNS to the intravascular system and filtration 
by dialysis [10]. Interestingly, the therapeutic range of 
baclofen 80–400 ng/mL has been found to cause 
negative side effects in patients with impaired renal 
function. The exact therapeutic level with the intended 
decrease in dosing remains unclear with continued 
susceptibility to adverse side effects 
[11].Electroencephalography (EEG) has been used in 
initial evaluations for the etiology of unconsciousness 
in baclofen overdose. These changes include pseudo 
periodic sharp waves to periodic high-amplitude 
discharges and generalized slow waves [12]. 
Resolution of these EEG changes was seen following 
treatment [13]. These changes did not indicate the 
capacity to induce epilepsy and have been 
recommended not to treat with antiepileptic 
medications [13]. Baclofen renal dosing continues to 
be nonspecific with renal adjustment 
recommendations. A study in 2011 highly 
recommended changes in labeling with improved 
guidelines in dosing. There was a proposal to avoid this 
medication with a GFR < 30 mL/min/1.73 m2. This was 
further detailed with a decrease in dosing and titrating 
in a GFR > 30 to 60 mL/min/1.73 m2 [14]. In following 
the reported history of decreased renal function and 
side effects, this continues to be a highly appropriate 
recommendation. Our case represents toxic 
encephalopathy with inappropriate dosing of baclofen 
that was resolved with hemodialysis. Special 
consideration is required with this renally excreted 
medication and more specific guidelines would likely 
further alleviate incidence of side effects. 
 
Conclusion 
Special consideration is required with this renally 
excreted medication and more specific guidelines 
would likely further alleviate incidence of side effects. 
It’s paramount that physicians are aware of such an 
interaction in ESRD patients.  
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